Adam C Vandervoort, who serves as Chief Legal Officer and Secretary at Teladoc Health, Inc. (NYSE: TDOC), sold 27,083 shares of common stock on March 2, 2026, at a price of $5.117 per share. The transaction produced proceeds of $138,583.
The sale follows an internal equity event earlier in the week: on February 27, 2026, Vandervoort acquired 53,590 shares of Teladoc Health common stock through the conversion of restricted stock units and performance stock units. The sequence - a conversion of incentive grants followed by a planned sale - is reflected in the filings disclosing the movements.
Market action around the stock has been volatile. Over the past week Teladoc shares have gained nearly 10%, yet the stock remains roughly 45% lower than it was a year ago. Those price moves frame the insider transaction and public commentary from analysts that followed the company’s quarterly report.
Quarterly results and analyst responses
Teladoc reported fourth-quarter 2025 results that slightly outperformed Street expectations. The company recorded earnings per share of -$0.14 versus a consensus forecast of -$0.18, representing a positive surprise of 22.22%. Revenue for the quarter was $642 million, a touch above the anticipated $635.31 million.
Analysts have reacted in differing ways. BofA Securities upgraded Teladoc Health to a Buy rating and set a $7.00 price target, citing an improved margin outlook for BetterHelp. By contrast, Stifel and Wells Fargo each lowered their price targets to $6.00 while keeping Hold and Equal Weight ratings, respectively. Stifel pointed to revenue pressures, and Wells Fargo highlighted a flat growth outlook along with challenges in member growth and a less favorable usage-based mix.
Together, these assessments underscore a divided view among sell-side analysts about Teladoc’s near-term performance and strategic positioning.
Valuation note
According to InvestingPro analysis, Teladoc appears undervalued at current levels, and the platform provides additional context through nine more ProTips for investors evaluating the telehealth company.
Implications
The combination of an insider sale after a conversion event, a modest quarterly beat, and mixed analyst commentary preserves uncertainty about the stock’s direction. Market participants will likely weigh the company’s operational performance and the revenue and member-growth signals flagged by analysts when assessing valuation and risk.